Differentiation of MDSPCs to a neurogenic lineage prior to implantation decreases their ability to respond to environmental cues and stops transformation. by Mitra Lavasani (343357)

IFN-λ1 decreases miR-122 transcription through down regulation of HNF4α. by Fatma Aboulnasr (736868)

“…The precipitated complexes were subjected to SDS-PAGE and Western blotting for HNF4α and PPAR-γ. <b>(E)</b> Quantification of the bands in Fig 5D <b>(F)</b> Schematic representation of putative HNF4α binding sites in human miR-122 gene promoters and the mechanisms for how IFN-λ1 decreases miR-122 transcription through reduced binding of HNF4α to DR1 element, **p≤0.01, ***p≤0.001.…”

Conceptual framework for Child Health and Nutrition Initiative (CHNRI) showing steps from health research investment to a decrease in burden of death, disease, or disability. by Joy E. Lawn (124331)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

MDSCs decrease the frequency of Th17 cells in mice with DSS-induced colitis. by Jing Zhang (23775)

“…A) Adoptive transfer of MDSCs decreased serum IL-17 level in DSS-treated WT mice. …”

Data from: Mistletoe host diversity decreases with elevation in a temperate rainforest of southern Chile: implications for frugivory by Victoria P. Fernández (11989404)

“…<p dir="ltr">Original data from:</p><p dir="ltr">Fontúrbel, F.E., J.I. Orellana, Fernández, V.P., G.C. Amico & R.F. …”

Inhibition of the EphA4-c-Abl pathway decreases the loss of dendritic spines and apoptosis induced by AβOs. by Lina M. Vargas (540995)

MEK1/2 inhibition promotes invasive-opposing leading edge lamellipodial structures in 3-D by increasing localised Rac1 activity and decreasing localised RhoA activity. by Joseph H. R. Hetmanski (2656735)

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Lansoprazole decreases IL-4-stimulated eotaxin-3 protein secretion in (A) EoE1-T and (2) EoE2-T cells. by Xi Zhang (83736)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)